-+ 0.00%
-+ 0.00%
-+ 0.00%

Kurma Partners-backed Minoryx drug NEZGLYAL wins positive EMA CHMP opinion for cALD treatment

PUBT·07/27/2026 14:31:12
Listen to the news
Kurma Partners-backed Minoryx drug NEZGLYAL wins positive EMA CHMP opinion for cALD treatment
  • EMA’s CHMP backed marketing authorization under exceptional circumstances for NEZGLYAL (leriglitazone) in male pediatric cALD patients.
  • Minoryx expects European Commission clearance by end-September 2026; Neuraxpharm holds European commercialization rights.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kurma Partners SA published the original content used to generate this news brief on July 27, 2026, and is solely responsible for the information contained therein.